Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies
- 1 February 2018
- journal article
- research article
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 71 (2), 246-253
- https://doi.org/10.1053/j.ajkd.2017.09.007
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Serum Phosphate as a Risk Factor for Cardiovascular Events in People with and without Chronic Kidney Disease: A Large Community Based Cohort StudyPLOS ONE, 2013
- Combined Use of Vitamin D Status and FGF23 for Risk Stratification of Renal OutcomeClinical Journal of the American Society of Nephrology, 2012
- Comparative Effectiveness of Calcium-Containing Phosphate Binders in Incident U.S. Dialysis PatientsClinical Journal of the American Society of Nephrology, 2011
- Serum Phosphate and Mortality in Patients with Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2010
- Outcomes Associated With Phosphorus Binders in Men With Non–Dialysis-Dependent CKDAmerican Journal of Kidney Diseases, 2010
- Longitudinal Relationships among Coronary Artery Calcification, Serum Phosphorus, and Kidney FunctionClinical Journal of the American Society of Nephrology, 2009
- Serum Phosphorus Levels Associate with Coronary Atherosclerosis in Young AdultsJournal of the American Society of Nephrology, 2009
- Phosphorus Binders and Survival on HemodialysisJournal of the American Society of Nephrology, 2009
- A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal diseaseBMC Nephrology, 2008
- Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patientsKidney International, 2007